Athira pharma reports full year 2022 financial results and recent pipeline and business updates

On track to complete enrollment in phase 2/3 lift-ad trial of fosgonimeton for mild-to-moderate alzheimer's disease in mid-2023 with topline data in early 2024

ATHA Ratings Summary

ATHA Quant Ranking